E Novavax Posts Positive Phase 2 Data For RSV-F, Stock Surges

Shares of Novavax (NVAX) closed up almost 25% today after the company reported positive phase 2 results for its RSV — Respiratory Syncytial Virus — vaccine. The patients that were treated in the trial using the company's RSV F-protein vaccine were age 60 and older and well tolerated  the vaccine in the doses given. 

The trial recruited 1,600 patients across 10 clinical sites in the United States to determine if the RSV F vaccine was superior to a placebo compound. The company also explored safety  to determine if there were any harsh reactions to the vaccine. 

This trial was the first to show efficacy in a population of RSV patients. Novavax's vaccine was able to show a prevention of RSV symptoms by 44% and a reduction of RSV disease of the lower respiratory tract by 46%. Not only did the company's vaccine show superior efficacy to placebo, it did so with a matched safety profile to placebo. 

Novavax will now show the detailed results of this trial at an upcoming scientific conference, where investors will get a deeper look into the data. In addition the company is expecting to release additional results for its RSV F vaccine currently in phase 2 clinical trials for infant protection via maternal immunization later this quarter. 

Print Friendly, PDF & Email
No tags for this post.

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *